LH Blood Test: Normal Ranges & Causes | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

LH blood test

Luteinizing hormone. Also called: Lutropin, Luteinizing hormone, ICSH

Biomarker guideLast updated: October 30, 2026

LH is the pituitary hormone that tells the testes to make testosterone and triggers ovulation in women. It is released in pulses, so one blood sample is a snapshot, and it is read together with FSH and the sex hormones.

LOINC 10501-5HormonesSexual

At a glance

What it measuresLuteinizing hormone, a pituitary gonadotropin that drives the testes and ovaries.
SampleBlood (serum or plasma). LH comes in pulses and, in women, changes through the cycle.
Typical adult rangeMen: 1.7-8.6 (Labcorp), 1.5-9.3 mIU/mL (Quest, 18-59). Women: varies by cycle phase; postmenopausal 7.7-58.5 (Labcorp).
Common reasons it reads highMenopause, primary testicular or ovarian failure, Klinefelter syndrome, castration, the mid-cycle surge and polycystic ovary syndrome.
Peptides that move itRaised by Kisspeptin-10 (in men) and pulsatile Gonadorelin. Suppressed by Leuprolide, Triptorelin, Goserelin and Nafarelin after an initial surge, and by Degarelix, Ganirelix and Cetrorelix.
Lab codeLOINC 10501-5 (Labcorp 004283, Quest 615)

What is LH?

Luteinizing hormone (LH) is a glycoprotein made by the pituitary gland. Together with FSH it belongs to the gonadotropin family and stimulates the growth and function of the ovaries and testes.

Labcorp uses LH to judge whether the hypothalamic-pituitary-gonadal axis is working, to tell primary gonadal failure from a lack of pituitary stimulation, and in diagnosing and treating infertility in women.

Sources: [1]

How it is made and regulated

Where it is made

Gonadotropin-releasing hormone (GnRH), a short peptide from the hypothalamus, stimulates the pituitary to release both LH and FSH.

Sources: [2]

What controls it

LH is released in bursts. In young men, secretory bursts came about every 72 minutes, and 95% of the day's LH was released in only 5 hours. Sex steroids feed back to slow the pulses, and in women the pattern changes through the cycle and with sleep.

Sources: [3] [4] [5]

How it travels in the blood

LH, like FSH, TSH and hCG, is made of two subunits (alpha and beta); LH has 121 amino acids, three sugar chains and a molecular weight of about 29,500.

Sources: [1]

How long it lasts

The alpha and beta subunits of LH disappear from the blood with initial half-times of 15-18 minutes, and intact LH about twice as long. Apparent half-times after natural pulses ranged from 34 to 233 minutes.

Sources: [6] [7]

What it does

LH drives the testes and ovaries together with FSH; in women both vary through the cycle and peak at the time of ovulation. Postmenopausal women produce far more LH: 294.6 IU per day against 39.9 before menopause.

Sources: [1] [6]

Reference ranges

LH ranges depend on sex, age and, in women, the phase of the menstrual cycle. Postmenopausal women and older men run higher.

Labcorp (test 004283)

Method: Electrochemiluminescence immunoassay (ECLIA). Labcorp test page (retrieved October 30, 2026).

GroupRange (mIU/mL)
Adult men1.7-8.6
Adult women, follicular phase2.4-12.6
Adult women, ovulation14.0-95.6
Adult women, luteal phase1.0-11.4
Adult women, postmenopausal7.7-58.5
Children and teens
GroupRange (mIU/mL)
Boys, 10 to 12 yearsBelow 0.2 to 7.8
Girls, 10 to 12 yearsBelow 0.2 to 11.9
Boys, 13 to 16 years1.3-9.8
Girls, 13 to 16 years0.5-41.7

Labcorp also lists ranges for newborns and young children on its page.

Quest Diagnostics (test 615)

Method: Immunoassay (IA). Quest Diagnostics test page (retrieved October 30, 2026).

GroupRange (mIU/mL)
Men, 18-59 years1.5-9.3
Men, 60 years and older1.6-15.2
Women, follicular phase1.9-12.5
Women, mid-cycle peak8.7-76.3
Women, luteal phase0.5-16.9
Women, postmenopausal10.0-54.7

Ranges as shown for Quest's East region; not established for pre-pubertal children with this assay.

mIU/mL is the same as IU/L. Quest bases its ranges on people after puberty and recommends a separate pediatric LH test for younger children. Quest's ranges are for its East region.

Sources: [1] [8]

What raises it

FactorHowHow much
Primary gonadal failureConditionWhen the testes or ovaries fail, feedback is lost and the pituitary releases more LH and FSH. Labcorp lists hypogonadism, anorchia, gonadal failure, Klinefelter syndrome, castration and alcoholism.No published magnitude [5] [1]
MenopausePhysiologyWith the ovaries no longer making estradiol, LH production rises several-fold.Production 294.6 vs 39.9 IU/24 h in postmenopausal vs premenopausal women [6] [1]
The mid-cycle surgePhysiologyLH surges just before ovulation; home ovulation kits detect it in urine.Labcorp ovulation range 14.0-95.6 mIU/mL [1] [9]
Polycystic ovary syndromeConditionLH, and the LH-to-FSH ratio, tend to be higher in PCOS, but the ratio is not diagnostic.LH 6.36 vs 4.34; LH:FSH ratio 1.25 vs 0.71 (PCOS vs controls) [10]
Kisspeptin and pulsatile GnRHPeptideKisspeptin stimulates GnRH neurons; pulsed gonadorelin restores LH in GnRH deficiency. See the peptide table below.Kisspeptin-10 bolus in men: LH 4.1 to 12.4 IU/L at 30 minutes [11] [12] [13]

What lowers it

FactorHowHow much
Pituitary or hypothalamic diseaseConditionLH and FSH are both low in pituitary or hypothalamic failure; Kallmann syndrome is an inborn GnRH deficiency with a poor sense of smell.No published magnitude [5] [14]
Short-term fastingNutritionFasting reversibly suppresses pulsatile LH secretion.No published magnitude [15]
Oral contraceptivesMedicationPulsatile LH release continues on the pill, but the number of LH pulses is reduced.No published magnitude [16]
Endurance trainingLifestyleHigh-mileage male runners had lower LH pulse amplitude and lower testosterone than controls at rest.No published magnitude [17]
GnRH agonists and antagonistsPeptideAgonists first surge LH, then suppress it; antagonists suppress it directly. See the peptide table below.Leuprolide: decreased LH within two to four weeks of continuous dosing [18]

Peptides that affect LH

How each peptide in our library has been shown to affect LH, strongest evidence first. GnRH agonists (leuprolide, triptorelin, goserelin, nafarelin, buserelin, deslorelin) are listed as "lowers", but each first causes a short LH surge; the size column gives both. "No clear effect" means LH was measured and did not change; "Unclear" means the results conflict.

PeptideEffect on LHSize of effectEvidence
GonadorelinRaises5 women with idiopathic hypogonadotropic hypogonadism, pulsatile gonadorelin 10 micrograms every 90 min by pump (sustained, pulsatile): LH 2.2 to 5.4 U/L after 1 week (P=0.028)Given in pulses, gonadorelin restored LH in women whose own GnRH signal was missing. Continuous dosing acts like other GnRH agonists and suppresses LH. [19]Human trials
HMG (Human Menopausal Gonadotropin)RaisesSingle dose (2 ampules) in 10 ovulatory women and 10 women with PCOS (acute): serum LH rose 33.8% in ovulatory women only; hMG itself contains LH activityhMG contains LH activity, so measured LH rose after a dose in women with normal cycles but not in PCOS. [20]Human trials
Kisspeptin-10RaisesHealthy men. Acute IV bolus 1 μg/kg: LH 4.1 to 12.4 IU/liter at 30 min; infusion 1.5 μg/kg·h raised LH pulse frequency from 0.7 to 1.0 pulses/h. Sustained: daily 8-h SC infusions for 12 days kept LH raised (+1.68 day 1, +1.14 day 12 vs -0.16 vehicle). Women: no LH rise in the follicular phase; rise in the preovulatory phaseKisspeptin-10 raises LH and speeds LH pulses in men; in women the response depends on the cycle phase. [11] [12] [13]Human trials
LeptinRaisesEight women with hypothalamic amenorrhea from strenuous exercise or low weight, recombinant human leptin for up to three months (sustained): mean LH and LH pulse frequency rose after two weeks; no values in the abstractIn women with low leptin from exercise or low weight, leptin replacement raised LH and its pulse frequency. [21]Human trials
OxytocinRaisesWomen aged 20-35 with a follicle over 14 mm, oxytocin infusion 256 mIU/min for 2 h vs saline (n = 8 each; acute): earlier onset of the LH surge (P < 0.01)A single pre-ovulatory oxytocin infusion brought the LH surge forward; there are no data on repeated dosing. [22]Human trials
TirzepatideRaisesMen with obesity and metabolic hypogonadism, tirzepatide 2.5 mg weekly for the first month then 5 mg, plus diet and walking, 2 months (28 men; controls: lifestyle only or testosterone gel), electrochemiluminescence immunoassay: LH 2.6 ± 0.3 to 4.5 ± 0.6 mIU/mL, higher than both control groupsA 2-month pilot in 28 men with obesity and low testosterone, not randomized; LH rose alongside weight loss. [23]Human trials
BuserelinLowersMen with advanced prostate cancer (8), 600 micrograms intranasally 3 times daily (sustained): LH rose first (acute rises on day 1 after a 500 microgram i.m. injection), then fell by 70 to 80% within 1 to 3 weeksA GnRH agonist: LH surges after the first dose, then falls by 70 to 80% within 1 to 3 weeks of continued use. No US FDA label. [24]Human trials
DeslorelinLowersChildren with central precocious puberty (29), 4 micrograms/kg/day s.c. (sustained), a dose described as known to suppress gonadotropins; when lowered to 1 microgram/kg/day the peak LH response to LHRH stimulation was highest (P < 0.025). No published deslorelin-specific initial-surge valuesSuppresses LH with continued daily use in children, with less suppression at the lowest dose. No US human label. [25]Human trials
GhrelinLowers6 healthy women, 50 micrograms ghrelin at 2200, 2300, 2400 and 0100 h vs placebo (crossover, one night, acute): LH AUC 4.01 vs 5.46 mIU/min·ml (P=0.031); LH pulses 2.3 vs 3.8 (P=0.007)Overnight ghrelin injections lowered LH secretion and slowed LH pulses in a small study of women. [26]Human trials
LiraglutideLowersOverweight women with PCOS, metformin plus liraglutide vs metformin alone for 12 weeks: LH 12.09 to 6.61 mIU/mL with the combination vs 11.97 to 9.77 with metformin (P = 0.036 between groups)Adding liraglutide to metformin lowered LH more than metformin alone in women with PCOS. [27]Human trials
SomatostatinLowersAcute infusion, normal menstruating women: somatostatin 5.55 micrograms/min for 180 min with an LH-RH bolus (100 micrograms) at 90 min - the LH response to LH-RH was significantly reduced. Basal LH not reported in the abstractBlunted the LH response to a GnRH (LH-RH) test in women during an infusion; no data on everyday LH levels or repeated dosing. [28]Human trials
DulaglutideNo clear effectSame PCOS trial: LH change -0.56 IU/L with dulaglutide vs +3.33 IU/L with diet alone (p = 0.205)No LH change in one randomized PCOS trial. [29]Human trials
ExenatideNo clear effectWomen with PCOS, exenatide vs metformin, 4 RCTs (163 vs 165 women, sustained): LH MD -0.78 (-2.03 to 0.48), P = 0.22No significant LH difference from metformin in PCOS trials. No data in men. [30]Human trials
GalaninNo clear effectAcute: 8 healthy men given a 90-min human galanin infusion (33 or 132 pmol/kg.min), and 13 ovulatory women given porcine galanin 500 micrograms IV: LH unchanged in bothGalanin infusions raised GH but did not change LH in men or women. [31] [32]Human trials
Human Chorionic Gonadotropin (hCG)No clear effectMen with hypogonadal symptoms and testosterone above 300 ng/dL, hCG 1000-3000 IU twice a week (sustained, average follow-up 41.7 weeks): LH 4.8 to 4.0 mIU/mL, no significant changehCG acts on the LH receptor itself; measured LH did not change significantly in men on hCG monotherapy. [33]Human trials
LanreotideNo clear effectEighteen patients with active acromegaly given somatostatin analogs (octreotide or lanreotide) for 4 weeks before surgery (sustained): no change in LH or FSH; no values in the abstract, and lanreotide was not reported separately from octreotideNo LH change in a small presurgical acromegaly study that pooled lanreotide with octreotide. [34]Human trials
MacimorelinNo clear effect28 healthy volunteers, single oral dose 0.5 and 0.75 mg/kg (acute), sampled to 120 min: no LH changeA single diagnostic dose did not change LH. [35]Human trials
Neuropeptide YNo clear effect6 normal men, single IV bolus of 100 micrograms NPY (acute): no effect on its own; given together with LHRH it potentiated the LHRH-induced LH riseNPY alone did not change LH in men; it only boosted the LH response to an LHRH injection. [36]Human trials
Corticotropin-Releasing Hormone (CRH)UnclearHumans, acute IV: no change in mean LH in 5 agonadal women (pulsatile hCRH 0.5-2.0 micrograms/kg) or in cycling and postmenopausal women (8-hour infusion), where LH peak amplitude even rose in postmenopausal women. Ovariectomized rhesus monkeys: 200 and 500 micrograms CRH lowered LH by 35% and 21% (oCRH)No LH fall in human studies; LH fell in monkeys. Results conflict across species. [37] [38] [39]Human trials
SermorelinUnclearAcute single IV dose. 20 short prepubertal children, GHRH 1-29 1 microgram/kg: a short-term, small LH rise (p < 0.01). Given together with LHRH plus TRH, GHRH(1-29)NH2 did not change the release of other pituitary hormonesUnclear: a small, short LH rise after one dose in children, but no change when given with other releasing hormones. [40] [41]Human trials
Thyrotropin-Releasing Hormone (TRH)UnclearAcute IV TRH 200 micrograms in ovulatory women: LH rose from 6.0 to 8.0 (follicular) and 4.8 to 7.6 mIU/mL (luteal) at 30 minutes. TRH infusion 2.0 microgram/min in normal men: no LH change. Oral TRH 50 mg 4 times a day for 7 days in postmenopausal women: no LH changeUnclear: IV TRH raised LH slightly in women, but an infusion in men and oral TRH in postmenopausal women did not. [42] [43] [44]Human trials
CetrorelixLowersWomen in controlled ovarian stimulation: LH suppression begins about one hour after 3 mg and two hours after 0.25 mg, and is maintained with continuous treatment; the label reports no initial release of gonadotropinsA GnRH antagonist: LH falls within hours with no initial gonadotropin release, per the label. [45]FDA label
DegarelixLowersMen with prostate cancer, single 240 mg dose: LH and FSH fall, followed by testosterone. In the phase III trial testosterone was at castrate level by day 3 in 96.1% on degarelix vs none on leuprolide, and the authors note no antiandrogen is needed to prevent clinical flareA GnRH antagonist: LH and FSH fall, followed by testosterone, which was at castrate level by day 3 in 96.1% of men vs none on leuprolide in the head-to-head trial. [46] [47]FDA label
GanirelixLowersWomen in IVF (daily SC injections, sustained): the label reports rapid, reversible suppression with no initial release of gonadotropins detected; LH suppression is more pronounced than FSH; LH recovers within 48 hours of stoppingA GnRH antagonist: LH falls without a detected initial surge and recovers within two days of stopping. [48]FDA label
GoserelinLowersImplant 3.6 mg every 28 days (sustained). Initial surge: an initial increase in serum LH after the first dose (label, men). Suppression: LH suppressed to follicular phase levels within four weeks (label, women) and maintained with continued useA GnRH agonist: LH rises at first, then is suppressed within about four weeks. [49]FDA label
LeuprolideLowersLupron Depot label: an initial increase in circulating LH (with a transient rise in gonadal steroids), then decreased LH with continuous administration, occurring within two to four weeks; no LH values givenA GnRH agonist: LH first surges, then falls with continued dosing within two to four weeks. [18]FDA label
NafarelinLowersSynarel label: at the onset nafarelin stimulates LH and FSH release (a temporary rise in gonadal steroid production); repeated dosing abolishes the stimulatory effect, and in children with precocious puberty the peak LH response to GnRH fell to a prepubertal response (<15 mlU/mL) within one monthA GnRH agonist: LH first rises, then the pituitary response is suppressed with continued dosing. [50]FDA label
TriptorelinLowersInitial surge: after the first dose "a transient surge in circulating levels of luteinizing hormone (LH)". Suppression: "usually 2 to 4 weeks after initiation of therapy, a sustained decrease in LH and FSH secretion" (Trelstar; Triptodur: by 4 weeks). Children with central precocious puberty, 22.5 mg every 24 weeks: stimulated LH ≤5 IU/L in 93.2% at month 6 (sustained)A GnRH agonist: LH rises after the first injection, then falls and stays suppressed within about 2-4 weeks. [51] [52] [53]FDA label
TesamorelinNo clear effectEgrifta SV label, verbatim: "No clinically significant changes in the levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH) and prolactin, were observed in patients receiving EGRIFTA in clinical trials." (sustained daily dosing; values not given). The sentence names LH only, not FSH, SHBG or estradiolThe label names LH among pituitary hormones that did not change meaningfully in the clinical trials. [54]FDA label
OctreotideUnclearSandostatin label: suppresses the LH response to GnRH (a stimulated, not basal, LH effect; no values). In nine insulin-dependent diabetic women given 100 micrograms twice daily for 7 days, gonadotropins did not fall significantlyThe label says octreotide blunts the GnRH-stimulated LH response; a small study found no significant LH change. [55] [56]FDA label
IrisinRaisesMale Wistar rats, irisin 200 ng/kg SC over 30 days (sustained), and Kurdish ewes, IV irisin 20 or 40 ng/kg every three days for 45 days: serum LH increasedIrisin raised LH in rats and sheep. No human data. [57] [58]Animal studies
Melanin-Concentrating HormoneRaisesEstrogen-primed ovariectomized female rats, MCH injected into the rostral or medial preoptic area (acute): LH release stimulated; injection into the zona incerta did not stimulate it and blocked a steroid-induced LH surge. No values in the abstractRat brain-injection data only; the effect depends on brain region. No human data. [59]Animal studies
MOTS-cRaises80 male Wistar rats (obese and non-obese), MOTS-c 10 or 100 µM infused into the brain ventricles for 14 days (sustained): serum LH rose (p < 0.05); no values in the abstractMale rat data with brain infusion only; raised LH. No human data. [60]Animal studies
AdropinLowersMale Wistar rats (n = 8 per group), adropin 40 μg/kg/day intraperitoneally for 10 days (sustained): circulating LH lower than control and sham (p < 0.001); 4 μg/kg/day had no significant effectOnly the high dose lowered LH, in one rat study. No human data. [61]Animal studies
C-Type Natriuretic PeptideLowersConscious rats, CNP 0.1, 1.0 or 2.0 nmole into the third cerebral ventricle (acute): dose-related fall in plasma LH; no direct effect on pituitary cellsLowers LH through the brain in rats. No human data. [62]Animal studies
ObestatinLowersPeripubertal female sheep, obestatin 25 μg/120 μL h-1 infused into the brain ventricles on three consecutive days (n = 14 per group): lower mean blood LH from lower pulse amplitude; no values in the abstractSheep brain-infusion data only; no human data. [63]Animal studies
Urocortin-2LowersFemale mice, central (brain) injection, acute: urocortin 2 rapidly inhibited LH pulses and disrupted the estradiol-induced evening LH surge, acting on kisspeptin cells via CRHR2Mouse data only, with the peptide injected into the brain. No human data. [64]Animal studies
Urocortin-3LowersOvariectomized female mice, urocortin 3 infused into the posterodorsal medial amygdala (acute): dose-dependent inhibition of LH pulsesMouse data only, with the peptide infused into one brain region. No human data. [65]Animal studies
VasotocinLowersOvariectomized conscious rats, arginine vasotocin 40 or 100 ng into the third ventricle (acute): plasma LH lowered; 5 micrograms IV gave only a slight depression at 60 minRat data only, mainly with brain injection. No human data. [66]Animal studies
Angiotensin IIINo clear effectOvariectomized, estradiol- and progesterone-primed female rats, injection into the anterior hypothalamus-preoptic area (acute): no significant change in blood LH (angiotensin II at the same site raised LH by 100%)A single 1987 rat brain-injection study found no LH effect. No human data. [67]Animal studies
BradykininNo clear effectConscious ovariectomized female rats, 25 micrograms into the third ventricle (acute): plasma LH no different from saline; intravenous bradykinin also had no effect on hormone levelsNo LH change in a 1980 rat study. No human data. [68]Animal studies
GHRP-2No clear effectConscious swine, acute IV doses of GHRP-2 (specificity study): plasma LH not affectedIn pigs, GHRP-2 released GH without changing LH. No human LH data. [69]Animal studies
GHRP-6No clear effectConscious swine, acute IV doses of GHRP-6 (specificity study): plasma LH not affectedIn pigs, GHRP-6 released GH without changing LH. No human LH data. [69]Animal studies
IpamorelinNo clear effectConscious swine, acute IV doses of Ipamorelin (specificity study): plasma LH not affectedIn pigs, Ipamorelin released GH without changing LH. No human LH data. [69]Animal studies

What high or low results can mean

A high result

A high LH with low testosterone (men) or low estradiol (women) means the gonads are not responding: primary hypogonadism, menopause or ovarian failure. A high LH can also simply be the mid-cycle surge.

  • Menopause
  • Primary testicular failure, including Klinefelter syndrome
  • Primary ovarian insufficiency
  • Polycystic ovary syndrome
  • The mid-cycle surge

Next step: Interpret with FSH, testosterone or estradiol and, in women, the cycle day. Because LH is pulsatile, a repeat or pooled sample may be needed.

Sources: [1] [5] [10]

A low result

A low or inappropriately normal LH with low sex hormones points to the pituitary or hypothalamus (secondary hypogonadism).

  • Pituitary or hypothalamic disease
  • Kallmann syndrome
  • Fasting or very low weight
  • Oral contraceptives
  • GnRH agonist or antagonist treatment

Next step: Further pituitary assessment may be needed, depending on the clinical picture. Tell the clinician about the pill, any hormone treatment or GnRH drugs.

Sources: [5] [14] [15]

How the test works

SampleLabcorp takes serum (preferred) or lithium-heparin plasma, not oxalate, EDTA or citrate plasma.
FastingNeither Labcorp nor Quest lists a fasting requirement for LH, though prolonged fasting suppresses LH pulses.
TimingIn women, note the cycle day: LH varies through the cycle and peaks at ovulation. Because LH comes in pulses, Labcorp notes that samples taken every 15-30 minutes and pooled reduce the effect of a single pulse. Stop high-dose biotin at least 72 hours before.
Lab differencesLabcorp uses an ECLIA and Quest an immunoassay. Quest recommends its separate pediatric LH assay for children before puberty.
RetestingLH varies a lot within a person: within-person variation was about 26% in men, the highest of the sex hormones studied.
Labcorp order code004283: Luteinizing Hormone (LH)
Quest Diagnostics order code615: LH
LOINC codes
  • 10501-5: Lutropin [Units/volume] in Serum or Plasma
LOINC 10501-5 on loinc.org

Sources: [1] [8] [70] [15] [71]

History

LH could be measured in blood once radioimmunoassays arrived in 1966. GnRH, the hormone that drives it, was identified in 1971, and kisspeptin, the signal upstream of GnRH, in 2003.

  1. 1966Midgley describes a radioimmunoassay for human chorionic gonadotropin and human LH, and LH is measured through the menstrual cycle. [72] [73]
  2. 1971The structure of gonadotropin-releasing hormone is identified: one peptide regulates both LH and FSH. [2]
  3. 1973Episodic (pulsatile) LH secretion in men is characterized by pulse analysis. [7]
  4. 1988Deconvolution analysis shows LH secretory bursts about every 72 minutes in healthy men. [3]
  5. 2003Loss-of-function mutations in the kisspeptin receptor GPR54 are shown to cause hypogonadotropic hypogonadism, revealing kisspeptin's role in puberty. [74] [75]

FAQ

What is a normal LH level?

For men, 1.7-8.6 mIU/mL at Labcorp and 1.5-9.3 at Quest (ages 18-59). For women it depends on the cycle: Labcorp's follicular range is 2.4-12.6, ovulation 14.0-95.6, luteal 1.0-11.4 and postmenopausal 7.7-58.5.

Sources: [1] [8]

Why is LH tested with FSH?

Together they show whether a sex-hormone problem starts in the gonads (both high) or in the pituitary or hypothalamus (both low or inappropriately normal).

Sources: [5] [1]

What does high LH with low testosterone mean?

It points to primary hypogonadism: the testes are not responding to LH. Causes include Klinefelter syndrome, testicular damage and castration.

Sources: [5] [76]

Why can one LH test be misleading?

LH is released in pulses, in men about every 72 minutes, and in women it changes through the cycle. Labcorp notes that pooling samples taken every 15-30 minutes reduces the effect of a single pulse.

Sources: [3] [1]

When should women test LH?

It depends on the question. Note the cycle day, because ranges differ by phase and LH surges at ovulation. Home ovulation kits detect the urine LH surge, and five kits tested were highly accurate.

Sources: [1] [9]

Is LH higher in PCOS?

Often. In one study LH averaged 6.36 vs 4.34 and the LH-to-FSH ratio 1.25 vs 0.71 in PCOS vs controls, but the ratio is not diagnostic on its own.

Sources: [10]

Does LH rise after menopause?

Yes. Postmenopausal women made 294.6 IU of LH a day against 39.9 before menopause, and Labcorp's postmenopausal range is 7.7-58.5 mIU/mL.

Sources: [6] [1]

What is Kallmann syndrome?

A rare inborn lack of GnRH with a reduced or absent sense of smell. Without GnRH, LH and FSH stay low and so do the sex hormones.

Sources: [14]

Does kisspeptin raise LH?

In men, yes: a Kisspeptin-10 bolus raised LH from 4.1 to 12.4 IU/L at 30 minutes, an infusion raised LH pulse frequency from 0.7 to 1.0 per hour, and daily infusions kept LH up for 12 days. In women in the follicular phase there was no LH rise.

Sources: [11] [12] [13]

Why does leuprolide first raise LH?

Leuprolide and other GnRH agonists first stimulate the pituitary, causing an initial increase in LH, then decrease LH with continuous dosing within two to four weeks. Antagonists such as Ganirelix do not cause the initial release: its label says "An initial release of endogenous gonadotropins has not been detected."

Sources: [18] [48]

Does hCG change LH?

In men with testosterone above 300 ng/dL taking Human Chorionic Gonadotropin (hCG) twice weekly, LH went from 4.8 to 4.0 mIU/mL, not a significant change.

Sources: [33]

Does tesamorelin change LH?

The Egrifta SV label reports no clinically significant changes in LH, along with TSH, ACTH and prolactin, in clinical trials of Tesamorelin.

Sources: [54]

References

  1. Labcorp. Test 004283: Luteinizing Hormone (LH). Use, special instructions, limitations, additional information, specimen requirements, reference range and LOINC map. labcorp.com/tests/004283/luteinizing-hormone-lh
  2. Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971;173(4001):1036-8. PMID 4938639
  3. Veldhuis JD, Johnson ML. In vivo dynamics of luteinizing hormone secretion and clearance in man: assessment by deconvolution mechanics. J Clin Endocrinol Metab. 1988;66(6):1291-300. PMID 3372689
  4. Rossmanith WG, Lauritzen C. The luteinizing hormone pulsatile secretion: diurnal excursions in normally cycling and postmenopausal women. Gynecol Endocrinol. 1991;5(4):249-65. PMID 1796747
  5. Labcorp. Test 004309: Follicle-stimulating Hormone (FSH). Use (conditions with high FSH and LH) and limitations. labcorp.com/tests/004309/follicle-stimulating-hormone-fsh
  6. Pepperell RJ, Kretser DM, Burger HG. Studies on the metabolic clearance rate and production rate of human luteinizing hormone and on the initial half-time of its subunits in man. J Clin Invest. 1975;56(1):118-26. PMID 1170215
  7. Santen RJ, Bardin CW. Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. J Clin Invest. 1973;52(10):2617-28. PMID 4729055
  8. Quest Diagnostics. Test code 615: LH. Test directory entry (East region): methodology, clinical significance, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/615/lh?cc=PHP
  9. Vanderhoff AC, Lanes A, Waldman I, et al. Similar accuracy and patient experience with different one-step ovulation predictor kits. Fertil Steril. 2025;123(3):499-505. PMID 39326629
  10. Saucedo de la Llata E, Moraga-Sánchez MR, Romeu-Sarrió A, et al. [LH-FSH ratio and Polycystic Ovary Syndrome: A forgotten test?]. Ginecol Obstet Mex. 2016;84(2):84-94. PMID 27290835
  11. George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-36. PMID 21632807
  12. Yeung AC, Phylactou M, Koysombat K, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. 2026;195(2):206-216. PMID 42549827
  13. Jayasena CN, Nijher GM, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011;96(12):E1963-72. PMID 21976724
  14. Kallmann Syndrome. In: StatPearls [Internet]. StatPearls Publishing; 2024. PMID 30855798
  15. Bergendahl M, Aloi JA, Iranmanesh A, et al. Fasting suppresses pulsatile luteinizing hormone (LH) secretion and enhances orderliness of LH release in young but not older men. J Clin Endocrinol Metab. 1998;83(6):1967-75. PMID 9626127
  16. Hemrika DJ, Slaats EH, Kennedy JC, et al. Pulsatile luteinizing hormone patterns in long term oral contraceptive users. J Clin Endocrinol Metab. 1993;77(2):420-6. PMID 8345046
  17. McColl EM, Wheeler GD, Gomes P, et al. The effects of acute exercise on pulsatile LH release in high-mileage male runners. Clin Endocrinol (Oxf). 1989;31(5):617-21. PMID 2627755
  18. LUPRON DEPOT (leuprolide acetate for depot suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
  19. Liu Z, Mao J, Wu X, et al. [Effectiveness and safety of pulsatile GnRH pump therapy on female patients with IHH]. Zhonghua Yi Xue Za Zhi. 2015;95(42):3432-5. PMID 26813133
  20. Anderson RE, Cragun JM, Chang RJ, et al. A pharmacodynamic comparison of human urinary follicle-stimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome. Fertil Steril. 1989;52(2):216-20. PMID 2502437
  21. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351(10):987-97. PMID 15342807
  22. Hull ML, Reid RA, Evans JJ, et al. Pre-ovulatory oxytocin administration promotes the onset of the luteinizing hormone surge in human females. Hum Reprod. 1995;10(9):2266-9. PMID 8530649
  23. La Vignera S, Cannarella R, Garofalo V, et al. Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study. Reprod Biol Endocrinol. 2025;23(1):92. PMID 40604795
  24. Huhtaniemi I, Nikula H, Rannikko S. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels. J Androl. 1987;8(6):355-62. PMID 3123445
  25. Pescovitz OH, Barnes KM, Cutler GB. Effect of deslorelin dose in the treatment of central precocious puberty. J Clin Endocrinol Metab. 1991;72(1):60-4. PMID 1898743
  26. Kluge M, Schüssler P, Schmidt D, et al. Ghrelin suppresses secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in women. J Clin Endocrinol Metab. 2012;97(3):E448-51. PMID 22259063
  27. Xing C, Zhao H, Zhang J, et al. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2022;13:945609. PMID 36060969
  28. Chiodera P, Volpi R, d'Amato L, et al. Inhibition by somatostatin of LH-RH-induced LH release in normal menstruating women. Gynecol Obstet Invest. 1986;22(1):17-21. PMID 2875017
  29. Zhang Y, Qu Z, Lu T, et al. Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients. 2023;15(3). PMID 36771262
  30. Ye ZR, Yan CQ, Liao N, et al. The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials. Reprod Sci. 2023;30(8):2349-2361. PMID 37002532
  31. Carey DG, Iismaa TP, Ho KY, et al. Potent effects of human galanin in man: growth hormone secretion and vagal blockade. J Clin Endocrinol Metab. 1993;77(1):90-3. PMID 7686918
  32. Giustina A, Gastaldi C, Bugari G, et al. Role of galanin in the regulation of somatotrope and gonadotrope function in young ovulatory women. Metabolism. 1995;44(8):1028-32. PMID 7543651
  33. Zucker I, Rainer Q, Pai RK, et al. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. Cureus. 2022;14(5):e25543. PMID 35800844
  34. Waśko R, Ruchała M, Sawicka J, et al. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest. 2000;23(1):12-8. PMID 10698045
  35. Urwyler SA, Lustenberger S, Drummond JR, et al. Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers. Pituitary. 2021;24(4):555-563. PMID 33615399
  36. Watanobe H, Nigawara T, Anzai J, et al. Neuropeptide Y potentiates the luteinizing hormone (LH) response to LH-releasing hormone in men. Biochem Biophys Res Commun. 1994;200(2):1111-7. PMID 8179590
  37. Thomas MA, Rebar RW, LaBarbera AR, et al. Dose-response effects of exogenous pulsatile human corticotropin-releasing hormone on adrenocorticotropin, cortisol, and gonadotropin concentrations in agonadal women. J Clin Endocrinol Metab. 1991;72(6):1249-54. PMID 1851183
  38. Fischer UG, Wood SH, Bruhn J, et al. Effect of human corticotropin-releasing hormone on gonadotropin secretion in cycling and postmenopausal women. Fertil Steril. 1992;58(6):1108-12. PMID 1459256
  39. Olster DH, Ferin M. Corticotropin-releasing hormone inhibits gonadotropin secretion in the ovariectomized rhesus monkey. J Clin Endocrinol Metab. 1987;65(2):262-7. PMID 3110201
  40. Gelander L, Lindstedt G, Selstam G, et al. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. Horm Res. 1989;31(5-6):213-20. PMID 2515143
  41. Looij BJ, Nieuwenhuijzen Kruseman AC, Mudde AH, et al. The interaction of growth hormone releasing hormone with other hypothalamic hormones on the release of anterior pituitary hormones. Clin Endocrinol (Oxf). 1986;24(2):149-56. PMID 2871949
  42. Colon JM, Lessing JB, Yavetz C, et al. The effect of thyrotropin-releasing hormone stimulation on serum levels of gonadotropins in women during the follicular and luteal phases of the menstrual cycle. Fertil Steril. 1988;49(5):809-12. PMID 3129315
  43. Bremner WJ, de Kretser DM, Burger HG. Increases in serum concentrations of follicle-stimulating hormone (FSH) during thyrotrophin-releasing hormone (TRH) infusions in normal men. Clin Endocrinol (Oxf). 1977;7(5):339-404. PMID 412626
  44. Lee SG, Lundy LE, Kashef M, et al. Influence of thyrotropin-releasing hormone on the postmenopausal female. Obstet Gynecol. 1975;45(1):25-6. PMID 803307
  45. CETROTIDE (cetrorelix acetate for injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
  46. FIRMAGON (degarelix) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b
  47. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-8. PMID 19035858
  48. Ganirelix Acetate Injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fb74ff-993a-49fe-8943-e029372b863e
  49. ZOLADEX (goserelin implant), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
  50. SYNAREL (nafarelin acetate) nasal spray, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6
  51. TRELSTAR (triptorelin pamoate for injectable suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3
  52. TRIPTODUR (triptorelin) for extended-release injectable suspension, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f41380e7-b830-432d-a5f5-a872932f107e
  53. Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29(11):1241-1248. PMID 26887034
  54. EGRIFTA SV (tesamorelin for injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
  55. SANDOSTATIN (octreotide acetate) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e2c9856-1836-49f0-9472-4dbeeb408f39
  56. Prelević GM, Wurzburger MI, Balint-Perić L. The effect of somatostatin analog octreotide (Sandostatin) on luteinizing hormone and ovarian steroids in insulin-dependent diabetic women without residual insulin secretion. Gynecol Endocrinol. 1992;6(4):259-63. PMID 1492581
  57. Shokrollahi B, Zandi MIK, Palani A, et al. EFFECTS OF IRISIN ON REPRODUCTIVE HORMONES, LIPID PROFILES, AND OXIDATIVE STRESS BIOMARKERS IN MALE RATS. Acta Endocrinol (Buchar). 2025;21(1):37-46. PMID 41798973
  58. Shokrollahi B, Sharifi F. Dose- and time-dependent effects of intravenous irisin administration on GnRH, LH, FSH, and estrogen in Kurdish ewes during the breeding season. Res Vet Sci. 2025;193:105737. PMID 40505589
  59. Murray JF, Hahn JD, Kennedy AR, et al. Evidence for a stimulatory action of melanin-concentrating hormone on luteinising hormone release involving MCH1 and melanocortin-5 receptors. J Neuroendocrinol. 2006;18(3):157-67. PMID 16454799
  60. Ozturk Öztürk DA, Erden Y, Tekin S. Central MOTS-c infusion affects reproductive hormones in obese and non-obese rats. Neurosci Lett. 2024;826:137722. PMID 38462167
  61. Eraslan E, Tanyeli A, Güler MC, et al. Neuroendocrine effects of exogenous adropin administration on the hypothalamic pituitary testicular axis in male rats. Turk J Med Sci. 2026;56(1):302-314. PMID 41816746
  62. Huang FL, Skala KD, Samson WK. Hypothalamic effects of C-type natriuretic Peptide on luteinizing hormone secretion. J Neuroendocrinol. 1992;4(3):325-30. PMID 21554613
  63. Szlis M, Wójcik-Gładysz A, Przybył BJ. Central obestatin administration affect the LH and FSH secretory activity in peripubertal sheep. Theriogenology. 2020;145:10-17. PMID 31982689
  64. McCosh RB, Bell HF, Kreisman MJ, et al. Suppression of Luteinizing Hormone Secretion in Female Mice by a Urocortin 2-CRHR2 Signaling Pathway. Endocrinology. 2025;166(5). PMID 40037626
  65. Ivanova D, Li XF, McIntyre C, et al. Urocortin3 in the Posterodorsal Medial Amygdala Mediates Stress-induced Suppression of LH Pulsatility in Female Mice. Endocrinology. 2021;162(12). PMID 34618891
  66. Vijayan E, Samson WK, McCann SM. Effects of arginine vasotocin on levels of plasma gonadotropins and prolactin in ovariectomized conscious rats. Proc Soc Exp Biol Med. 1983;173(1):153-8. PMID 6407023
  67. Steele MK. Effects of angiotensins injected into various brain areas on luteinizing hormone release in female rats. Neuroendocrinology. 1987;46(5):401-5. PMID 3431655
  68. Steele MK, Negro-Vilar A, McCann SM. Effect of central injection of bradykinin and bradykinin potentiating factor upon release of anterior pituitary hormones in ovariectomized female rats. Peptides. 1980;1(3):201-5. PMID 6785730
  69. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822
  70. LOINC 10501-5: Lutropin [Units/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/10501-5
  71. Røys EÅ, Guldhaug NA, Viste K, et al. Sex Hormones and Adrenal Steroids: Biological Variation Estimated Using Direct and Indirect Methods. Clin Chem. 2023;69(1):100-109. PMID 36373220
  72. Midgley AR. Radioimmunoassay: a method for human chorionic gonadotropin and human luteinizing hormone. Endocrinology. 1966;79(1):10-8. PMID 5950482
  73. Midgley AR, Jaffe RB. Human luteinizing hormone in serum during the menstrual cycle: determination by radioimmunoassay. J Clin Endocrinol Metab. 1966;26(12):1375-81. PMID 5959528
  74. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-27. PMID 14573733
  75. de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003;100(19):10972-6. PMID 12944565
  76. Nieschlag E. Klinefelter syndrome: the commonest form of hypogonadism, but often overlooked or untreated. Dtsch Arztebl Int. 2013;110(20):347-53. PMID 23825486

Educational information, not medical advice. Lab ranges and test codes were checked on October 30, 2026. Always use the range printed on your own report, and talk to a clinician about your results.